Can the shingles vaccine protect transplant patients? new study aims to find out

NCT ID NCT06262776

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Central Adelaide Local Health Network Incorporated Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the shingles vaccine (SHINGRIX) in 160 people: transplant recipients on different immunosuppressant drugs and their healthy housemates. Researchers will measure immune responses at five time points over a year to see if the vaccine works well in these groups. The goal is to understand how different medications affect vaccine effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Recombinant zoster vaccine adjuvanted (SHINGRIX)
What this could lead to: If it works, this could show that the shingles vaccine is effective for transplant patients on various immunosuppressants, helping protect them from shingles.
What could go wrong: This is an early-phase study with only 160 participants, so results may not apply to all transplant patients. The vaccine might not produce strong immunity in those on certain medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNOSUPPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney failure herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IMMUNOSUPPRESSION VACCINE RESPONSE IMPAIRED

Contacts and locations

Locations

Royal Adelaide Hospital
RECRUITING

Adelaide, South Australia, 5000, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.